Regenxbio (RGNX) Income from Continuing Operations (2014 - 2025)

Regenxbio's Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 89821000.0 for Q4 2025.

• On a quarterly basis, Income from Continuing Operations rose 234.83% year-over-year to 89821000.0 in Q4 2025; TTM through Dec 2025 was 43017000.0, a 83.11% increase from a year earlier, with the FY2025 full-year figure at 535557000.0, down 132.24% from the prior year.
• Income from Continuing Operations advanced to 89821000.0 in Q4 2025 per RGNX's latest filing, from 65482000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 294023000.0 in Q4 2021 and bottomed at 76723000.0 in Q1 2022.
• The 5-year median for Income from Continuing Operations is 62418500.0 (2023), against an average of 18734700.0.
• Biggest YoY gain for Income from Continuing Operations was 735.85% in 2021; the steepest drop was 764.37% in 2021.
• Year by year, Income from Continuing Operations stood at 294023000.0 in 2021, then fell by 5.04% to 279207000.0 in 2022, then plunged by 122.55% to 62969000.0 in 2023, then decreased by 5.8% to 66620000.0 in 2024, then surged by 234.83% to 89821000.0 in 2025.
• Per Business Quant, the three latest RGNX Income from Continuing Operations figures stand at 89821000.0 (Q4 2025), 65482000.0 (Q3 2025), and 70892000.0 (Q2 2025).